A phase II study of pegylated liposomial doxorubicin (PLD) and gemcitabine (G) in the treatment of hepatocellular carcinoma (HCC) not suitable for loco-regional therapy

Davide Pastorelli,G. Cartei,Fable Zustovich,S. Zovato,G. Artioli,R. Ceravolo,Maria Ornella Nicoletto,S. Binato,M. Mattiazzi

A phase II study of pegylated liposomial doxorubicin (PLD) and gemcitabine (G) in the treatment of hepatocellular carcinoma (HCC) not suitable for loco-regional therapy

2007

Davide Pastorelli
G. Cartei
Fable Zustovich
S. Zovato
G. Artioli
R. Ceravolo
Maria Ornella Nicoletto
S. Binato
M. Mattiazzi

4585 Background: There is no gold standard pharmacological treatment for HCC not suitable for loco-regional therapy. Antracyclines have been often used for the chemotherapy of HCC with low efficacy...

Keywords:

Gemcitabine
Hepatocellular carcinoma
Cancer research
Doxorubicin
Oncology
Medicine
Internal medicine
Phases of clinical research
pharmacological treatment
Chemotherapy

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations